Estudios en fase III del edoxabán

Q4 Medicine

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI:10.1016/S1131-3587(16)30019-X

Iñaki Lekuona Goya

引用次数: 0

Abstract

Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.

查看原文本刊更多论文

依多沙班的第三阶段研究

依多沙班已在iii期试验中进行了广泛的研究，例如用于治疗非瓣膜性心房颤动(ENGAGE AF-TIMI 48研究)、预防静脉血栓栓塞复发(Hokusai-VTE研究)和预防骨科手术后血栓栓塞(STARS研究)。此外，最近发表的一些关键试验的亚分析值得考虑:这些研究涉及接受胺碘酮治疗的患者的不同亚型卒中和外周栓塞以及老年患者的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.